Legal & General Group PLC Sage Therapeutics, Inc. Transaction History

Legal & General Group PLC

  • $357 Billion
  • Q1 2025

A detailed history of Legal & General Group PLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 9,746 shares of SAGE stock, worth $63,641. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,746
Previous 65,924 85.22%
Holding current value
$63,641
Previous $357,000 78.43%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$5.55 - $8.66 $311,787 - $486,501
-56,178 Reduced 85.22%
9,746 $77,000
Q4 2024

Feb 13, 2025
SELL
$4.78 - $8.57 $3,432 - $6,153
-718 Reduced 1.08%
65,924 $357,000
Q3 2024

Feb 28, 2025
SELL
$7.02 - $13.08 $29,954 - $55,812
-4,267 Reduced 6.47%
61,657 $444,000
Q3 2024

Nov 14, 2024
BUY
$7.02 - $13.08 $17,943 - $33,432
2,556 Added 3.99%
66,642 $480,000
Q2 2024

Aug 14, 2024
BUY
$10.58 - $17.9 $45,462 - $76,916
4,297 Added 7.19%
64,086 $695,000
Q1 2024

May 14, 2024
BUY
$18.62 - $26.95 $27,464 - $39,751
1,475 Added 2.53%
59,789 $1.12 Million
Q4 2023

Feb 15, 2024
BUY
$17.1 - $22.26 $14,278 - $18,587
835 Added 1.45%
58,314 $1.26 Million
Q3 2023

Nov 14, 2023
SELL
$16.75 - $48.98 $6,733 - $19,689
-402 Reduced 0.69%
57,479 $1.18 Million
Q2 2023

Aug 14, 2023
BUY
$40.65 - $59.54 $308,980 - $452,563
7,601 Added 15.12%
57,881 $2.72 Million
Q1 2023

May 15, 2023
BUY
$37.27 - $46.57 $193,133 - $241,325
5,182 Added 11.49%
50,280 $2.11 Million
Q4 2022

Feb 14, 2023
SELL
$32.2 - $43.61 $4,926 - $6,672
-153 Reduced 0.34%
45,098 $1.72 Million
Q3 2022

Nov 14, 2022
SELL
$32.28 - $43.27 $123,083 - $164,988
-3,813 Reduced 7.77%
45,251 $1.77 Million
Q2 2022

Aug 22, 2022
SELL
$27.52 - $37.99 $1.19 Million - $1.64 Million
-43,243 Reduced 46.85%
49,064 $1.59 Million
Q1 2022

May 16, 2022
BUY
$30.71 - $45.71 $197,649 - $294,189
6,436 Added 7.49%
92,307 $3.06 Million
Q4 2021

Feb 14, 2022
SELL
$37.06 - $47.11 $290,253 - $368,965
-7,832 Reduced 8.36%
85,871 $3.65 Million
Q3 2021

Nov 15, 2021
BUY
$40.26 - $57.37 $404,935 - $577,027
10,058 Added 12.02%
93,703 $4.15 Million
Q2 2021

Aug 12, 2021
BUY
$54.88 - $79.29 $2.83 Million - $4.09 Million
51,610 Added 161.11%
83,645 $4.75 Million
Q1 2021

May 17, 2021
BUY
$70.65 - $96.76 $29,884 - $40,929
423 Added 1.34%
32,035 $2.4 Million
Q4 2020

Feb 12, 2021
SELL
$58.41 - $89.06 $626,739 - $955,613
-10,730 Reduced 25.34%
31,612 $2.74 Million
Q3 2020

Nov 13, 2020
BUY
$41.13 - $62.45 $22,909 - $34,784
557 Added 1.33%
42,342 $2.59 Million
Q2 2020

Aug 14, 2020
BUY
$25.95 - $43.15 $64,537 - $107,314
2,487 Added 6.33%
41,785 $1.74 Million
Q1 2020

May 14, 2020
SELL
$26.15 - $77.24 $7,400 - $21,858
-283 Reduced 0.71%
39,298 $1.13 Million
Q4 2019

Feb 13, 2020
BUY
$60.18 - $154.77 $297,469 - $765,028
4,943 Added 14.27%
39,581 $2.86 Million
Q3 2019

Nov 13, 2019
BUY
$140.29 - $189.96 $644,492 - $872,676
4,594 Added 15.29%
34,638 $4.86 Million
Q2 2019

Aug 14, 2019
BUY
$157.85 - $183.09 $726,267 - $842,397
4,601 Added 18.08%
30,044 $5.5 Million
Q1 2019

May 15, 2019
BUY
$89.33 - $163.65 $214,749 - $393,414
2,404 Added 10.43%
25,443 $4.05 Million
Q4 2018

Feb 15, 2019
BUY
$81.94 - $139.71 $155,849 - $265,728
1,902 Added 9.0%
23,039 $2.21 Million
Q3 2018

Nov 20, 2018
BUY
$138.11 - $169.04 $2,900 - $3,549
21 Added 0.1%
21,137 $2.99 Million
Q2 2018

Aug 10, 2018
BUY
$140.36 - $175.76 $496,172 - $621,311
3,535 Added 20.11%
21,116 $3.31 Million
Q1 2018

May 17, 2018
BUY
$152.15 - $192.33 $95,702 - $120,975
629 Added 3.71%
17,581 $2.83 Million
Q4 2017

Feb 13, 2018
BUY
$60.72 - $167.34 $1.03 Million - $2.84 Million
16,952
16,952 $2.8 Million

Others Institutions Holding SAGE

# of Institutions
217
Shares Held
49.9M
Call Options Held
220K
Put Options Held
312K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $388M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email